Literature DB >> 22226999

Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons.

Takuto Hideyama1, Takenari Yamashita, Hitoshi Aizawa, Shoji Tsuji, Akiyoshi Kakita, Hitoshi Takahashi, Shin Kwak.   

Abstract

Amyotrophic lateral sclerosis (ALS) is the most common adult-onset fatal motor neuron disease. In spinal motor neurons of patients with sporadic ALS, normal RNA editing of GluA2, a subunit of the L-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, is inefficient. Adenosine deaminase acting on RNA 2 (ADAR2) specifically mediates RNA editing at the glutamine/arginine (Q/R) site of GluA2 and motor neurons expressing Q/R site-unedited GluA2 undergo slow death in conditional ADAR2 knockout mice. Therefore, investigation into whether inefficient ADAR2-mediated GluA2 Q/R site-editing occurs universally in motor neurons of patients with ALS would provide insight into the pathogenesis of ALS. We analyzed the extents of GluA2 Q/R site-editing in an individual laser-captured motor neuron of 29 ALS patients compared with those of normal and disease control subjects. In addition, we analyzed the enzymatic activity of three members of the ADAR family (ADAR1, ADAR2 and ADAR3) in ALS motor neurons expressing unedited GluA2 mRNA and those expressing only edited GluA2 mRNA. Q/R site-unedited GluA2 mRNA was expressed in a significant proportion of motor neurons from all of the ALS cases examined. Conversely, motor neurons of the normal and disease control subjects expressed only edited GluA2 mRNA. ADAR2, but not ADAR1 or ADAR3, was significantly downregulated in all the motor neurons of ALS patients, more extensively in those expressing Q/R site-unedited GluA2 mRNA than those expressing only Q/R site-edited GluA2 mRNA. These results indicate that ADAR2 downregulation is a profound pathological change relevant to death of motor neurons in ALS.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22226999     DOI: 10.1016/j.nbd.2011.12.033

Source DB:  PubMed          Journal:  Neurobiol Dis        ISSN: 0969-9961            Impact factor:   5.996


  78 in total

Review 1.  Epigenetics in amyotrophic lateral sclerosis: a role for histone post-translational modifications in neurodegenerative disease.

Authors:  Seth A Bennett; Royena Tanaz; Samantha N Cobos; Mariana P Torrente
Journal:  Transl Res       Date:  2018-10-12       Impact factor: 7.012

Review 2.  A critical analysis of codon optimization in human therapeutics.

Authors:  Vincent P Mauro; Stephen A Chappell
Journal:  Trends Mol Med       Date:  2014-09-25       Impact factor: 11.951

Review 3.  Amyotrophic lateral sclerosis: mechanisms and therapeutics in the epigenomic era.

Authors:  Ximena Paez-Colasante; Claudia Figueroa-Romero; Stacey A Sakowski; Stephen A Goutman; Eva L Feldman
Journal:  Nat Rev Neurol       Date:  2015-04-21       Impact factor: 42.937

Review 4.  The emerging role of RNA editing in plasticity.

Authors:  Joshua J C Rosenthal
Journal:  J Exp Biol       Date:  2015-06       Impact factor: 3.312

5.  ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.

Authors:  Stephen Moore; Eric Alsop; Ileana Lorenzini; Alexander Starr; Benjamin E Rabichow; Emily Mendez; Jennifer L Levy; Camelia Burciu; Rebecca Reiman; Jeannie Chew; Veronique V Belzil; Dennis W Dickson; Janice Robertson; Kim A Staats; Justin K Ichida; Leonard Petrucelli; Kendall Van Keuren-Jensen; Rita Sattler
Journal:  Acta Neuropathol       Date:  2019-04-03       Impact factor: 17.088

6.  Explaining Pathogenicity of Congenital Zika and Guillain-Barré Syndromes: Does Dysregulation of RNA Editing Play a Role?

Authors:  Helen Piontkivska; Noel-Marie Plonski; Michael M Miyamoto; Marta L Wayne
Journal:  Bioessays       Date:  2019-05-20       Impact factor: 4.345

Review 7.  ADAR RNA editing in human disease; more to it than meets the I.

Authors:  Angela Gallo; Dragana Vukic; David Michalík; Mary A O'Connell; Liam P Keegan
Journal:  Hum Genet       Date:  2017-09-14       Impact factor: 4.132

Review 8.  Antisense oligonucleotide therapy for the treatment of C9ORF72 ALS/FTD diseases.

Authors:  Giulietta Riboldi; Chiara Zanetta; Michela Ranieri; Monica Nizzardo; Chiara Simone; Francesca Magri; Nereo Bresolin; Giacomo P Comi; Stefania Corti
Journal:  Mol Neurobiol       Date:  2014-05-09       Impact factor: 5.590

Review 9.  RNA-binding proteins in neurodegeneration: Seq and you shall receive.

Authors:  Julia K Nussbacher; Ranjan Batra; Clotilde Lagier-Tourenne; Gene W Yeo
Journal:  Trends Neurosci       Date:  2015-03-09       Impact factor: 13.837

10.  A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology.

Authors:  Takenari Yamashita; Takuto Hideyama; Kosuke Hachiga; Sayaka Teramoto; Jiro Takano; Nobuhisa Iwata; Takaomi C Saido; Shin Kwak
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.